Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients (NCT07242482) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients
China200 participantsStarted 2025-12-17
Plain-language summary
Investigating the Clinical Value of Tumor Antigen-Specific T Cells and Immune Cell Balance in Peripheral Blood of Non-Small Cell Lung Cancer Patients for Prognostic Evaluation.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 18 to 80 years.
* Diagnosed with primary non-small cell lung cancer (NSCLC) and scheduled to undergo curative lung resection at the Department of Thoracic Surgery of our institution.
* Postoperative pathological stage is IB (with tumor size \>4cm or high-risk factors: poor differentiation, vascular invasion, visceral pleural invasion, sub-lobar resection, etc.), IIA, IIB, or IIIB (according to the AJCC 8th edition).
* ECOG performance status of 0 or 1.
* Voluntarily signs the informed consent form.
Exclusion Criteria:
* Received any neoadjuvant therapy prior to surgery.
* History of other active malignancies.
* Diagnosed with severe autoimmune diseases, active infections, or immunodeficiency disorders.
* Presence of severe cardiac, hepatic, or renal dysfunction.
* Pregnant or lactating women.